trending Market Intelligence /marketintelligence/en/news-insights/trending/dgj6YFzDkaL695hTf8ULFw2 content esgSubNav
In This List

Yunnan Hongxiang Q1 profit falls YOY

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Earnings forecasts for US banks; corporate deleveraging; LatAm currency gains

Blog

Insight Weekly: M&A slows down; climate tops proxy season; private equity pours into blockchain


Yunnan Hongxiang Q1 profit falls YOY

Yunnan Hongxiang Yixintang Pharmaceutical Co. Ltd. said its normalized net income for the first quarter came to 13 fen per share, a decline of 16.2% from 15 fen per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 65.4 million yuan, a decrease of 16.1% from 78.0 million yuan in the prior-year period.

The normalized profit margin declined to 4.5% from 6.5% in the year-earlier period.

Total revenue rose 23.2% on an annual basis to 1.48 billion yuan from 1.20 billion yuan, and total operating expenses increased 26.7% year over year to 1.37 billion yuan from 1.08 billion yuan.

Reported net income grew 16.8% year over year to 105.8 million yuan, or 20 fen per share, from 90.6 million yuan, or 17 fen per share.

As of April 25, US$1 was equivalent to 6.49 yuan.